HUGE FSD Pharma Net earnings per share for the last 12 months

Trailing twelve-month earnings per share on the GURU.Markets chart shows a decline for FSD Pharma Inc. (HUGE) due to austerity measures and the liquidation of non-core assets. This results from a strategic focus on developing precision drugs for neurodegeneration and strong confidence among scientists in the company's methods for combating brain inflammation. The value of -0.26 determines the current status of the parameter, helping investors assess real profit without market noise.

HUGE FSD Pharma Earnings per share for the trailing year (07/04/2022 - 08/15/2024)

fsdpharma.com - analytical breakdowns and key metrics (HUGE)

- stock price and consensus target price:

Stock Price FSD Pharma Inc.|HUGE - Average Forecast Price

- market capitalization data:

Market Valuation FSD Pharma Inc.|HUGE - Enterprise Value

- balance sheet net asset value indicators:

Net Assets per Single Share FSD Pharma|HUGE - Accounting Value of Company|Market Value to Book Value Ratio fsdpharma.com|HUGE - Company Assets

- debt level and financial liquidity data:

- earnings and multiples data:

HUGE - Profit After Tax|Expected Profit FSD Pharma Inc.|HUGE - Business Payback Period|Forward P/E Multiple FSD Pharma Inc.|HUGE - Growth-Adjusted P/E Ratio|Enterprise Value to EBITDA Ratio FSD Pharma Inc.|HUGE - Income before deduction of interest, taxes and amortization|Earnings per share for the last twelve months FSD Pharma|HUGE - Earnings per one share for the last 12 months|Quarterly EPS earnings growth fsdpharma.com|HUGE - Earnings per share increase in current year|Earnings growth forecast for next year FSD Pharma Inc.

- issuer revenue and sales details:

HUGE - Revenue and Sales Volume|Company Projected Revenue FSD Pharma|HUGE - Market Capitalization-to-Revenue Ratio|Price-to-Projected Revenue Ratio FSD Pharma Inc.

Basic company analysis:FSD Pharma Inc. (HUGE)

For the biotech company FSD Pharma Inc. (HUGE), which focuses on developing treatments for depression and PTSD, operational efficiency is driven by clinical trial expenditures. This indicator is calculated as the ratio of annual net income to the number of non-diluted shares. The metric allows for an assessment of the real return per share by excluding the impact of issuance factors. It is critical for investors to track capital dynamics amid the optimization of the patent portfolio. Analyzing the rolling net income per share helps identify business consolidation phases in a timely manner.

Analysis of competing companies